Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Lactoferrin as a regenerative agent: The old-new panacea?

Antoshin AA., Shpichka AI., Huang G., Chen K., Lu P., Svistunov AA.

Narrative Review on Tendon Injury, Chronic Inflammation, Immune Modulation, published in Pharmacol Res (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Pharmacol Res (2021)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
33744427
DOI
10.1016/j.phrs.2021.105564

Abstract (original English)

Lactoferrin (Lf) possesses various biological properties and therapeutic potentials being a perspective anti-inflammatory, antibacterial, antiviral, antioxidant, antitumor, and immunomodulatory agent. A significant body of literature has also demonstrated that Lf modulates regenerative processes in different anatomical structures, such as bone, cartilage, skin, mucosa, cornea, tendon, vasculature, and adipose tissue. Hence, this review collected and analyzed the data on the regenerative effects of Lf, as well as paid specific attention to their molecular basis. Furthermore, tissue and condition-specific activities of different Lf types as well as problems of their delivery to the targeted organs were discussed. The authors strongly hope that this review will stimulate researchers to focus on the highlighted topics thus accelerating the progress of Lf's wider clinical application.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsAnti-Infective AgentsAnti-Inflammatory AgentsAntioxidantsHumansLactoferrinRegenerationRegenerative MedicineStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research